附带降解的 PROTACs:是时候退车了吗?
Zhe Gavin Gao1, Kevin Burgess1
1Department of Chemistry, Texas A & M University, Box 30012, College Station, Texas 77842, United States.
ACS medicinal chemistry letters
|February 18, 2026
概括
在药物开发中,通常会避免非目标效应. 然而,对于蛋白质解析向嵌合体 (PROTACs) 和其他降解剂,当向蛋白质复合体时,这些效应可能是有益的.
科学领域:
- 药物开发 药物开发
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 在药物研发中,非目标效应通常被认为是有害的.
- 在药物设计中,非目标活动的实用性是一个尚未探索的领域.
- 蛋白质溶解向奇默体 (PROTACs) 和类似的分子降解剂提供了新的治疗方式.
研究的目的:
- 在药物开发中调查非目标效应的潜在优势.
- 探索针对多蛋白质复合体而不是单一蛋白质在治疗上具有相关性的场景.
- 在新型降解剂 (如PROTACs) 的背景下重新评估非目标活动的作用.
主要方法:
- 文献综述和药物向相互作用的理论分析.
- 对现有的PROTACs和分子降解剂的案例研究分析.
- 蛋白质与蛋白质相互作用网络的生物信息分析.
主要成果:
- 当治疗目标涉及调节多蛋白质复合体的功能时,对PROTACs和降解剂而言,非目标效应可能是有利的.
- 在某些疾病背景下,目标蛋白的活性可能不如蛋白质复合物的集体功能那么关键.
- 了解复杂级别的相互作用可以指导设计更有效的降解剂.
结论:
- 传统的观点认为非目标效应仅仅是不必要的需要修改,特别是复杂向剂.
- PROTAC和其他降解剂提供了利用非目标活动获得治疗益处的机会.
- 未来的药物开发策略应该考虑通过精心设计的目标外相互作用来调节多蛋白复合体.
相关概念视频
01:28Acute Coronary Syndrome IV: Interprofessional Care
313
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
313
01:16Clot Retraction and Fibrinolysis
9.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.4K
01:30Acute Coronary Syndrome I: Introduction
1.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.1K
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
477
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
477
02:58Regulated Protein Degradation
3.2K
3.2K
02:58Regulated Protein Degradation
9.0K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
9.0K